Predictive and prognostic biomarkers of immune checkpoint inhibitors in renal cell, urothelial, and other urological carcinomas

Predictive and prognostic biomarkers of immune checkpoint inhibitors in renal cell, urothelial, and other urological carcinomas - BINIR study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025086

Enrollment

100

Registered

2016-12-01

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell cercinoma urothelial carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable or metastatic renal cell carcinoma who will be treated with immune checkpoint inhibitorsr and patients with unresectable or metastatic urothelial carcinoma who will be treated with immune checkpoint inhibitorsr will be recruited.

Exclusion criteria

Exclusion criteria: Patients who are pregnant or have past history of allergy to immune checkpoint inhibitorsr will be excluded.

Design outcomes

Primary

Measure	Time frame
The difference of progression-free survival (PFS) according to serumchemoline levels and T cell receptor (TCR) repertoire	—

Secondary

Measure	Time frame
The relationship between survivals and , regulatory T cells, MDSC, or other chemokines	—

Countries

Japan

Contacts

Public ContactKouji Izumi

Kanazawa University Department of Integrative Cancer Therapy and Urology

azuizu2003@yahoo.co.jp076-265-2393

Outcome results